| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 30th September 2020 | Jennifer Schranz | 301 | Payment by withholding | $0.53 | $160.43 |
| 30th September 2020 | Robert Crotty | 366 | Payment by withholding | $0.53 | $195.08 |
| 30th September 2020 | Theodore R Schroeder | 1,211 | Payment by withholding | $0.53 | $645.46 |
| 30th September 2020 | Francesco Maria Lavino | 366 | Payment by withholding | $0.53 | $195.08 |
| 30th September 2020 | Gary Sender | 312 | Payment by withholding | $0.53 | $166.30 |
| 30th September 2020 | Steven P. Gelone | 628 | Payment by withholding | $0.53 | $334.72 |
| 31st August 2020 | Gary Sender | 312 | Payment by withholding | $0.62 | $193.25 |
| 31st August 2020 | Francesco Maria Lavino | 366 | Payment by withholding | $0.62 | $226.70 |
| 31st August 2020 | Jennifer Schranz | 301 | Payment by withholding | $0.62 | $186.44 |
| 31st August 2020 | Steven P. Gelone | 628 | Payment by withholding | $0.62 | $388.98 |
Nabriva Therapeutics Plc
Nabriva Therapeutics Plc is a clinical stage biopharmaceutical company. It engages in the research and development of novel antibiotics to treat serious infections. The company was founded in October 2005 and is headquartered in Dublin, Ireland.
Ticker: NBRV
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1641640
Employees: 162
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
We weren't able to import Fundamental data from the SEC disclosure.
There were no Red Flags found
Fundamentals
We weren't able to import Fundamental data from the SEC disclosure.
